A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma

Trial Profile

A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate-067
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results of Gastrointestinal toxicity management in patients from phase II and III trials (CheckMate 069 and CheckMate 067; n=327) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 24 May 2017 Results assessing predictors of utility over time in treatment-naive advanced melanoma patients (n=916), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top